Emergency Use Pathways
Sasha explains the different regulatory pathways for pharmaceuticals, highlighting the unique emergency use countermeasure that bypasses traditional requirements like informed consent and ethical oversight. This pathway, activated during public health emergencies, allows products to be marketed without the usual restrictions, raising significant implications for safety and accountability.In this clip
From this podcast

Doc Malik
#152 - Sasha Latypova On The COVID-19 Pandemic And Its Underlying Agenda
Related Questions